
    
      After being informed about the study and potential risks, all patients giving written
      informed consent will undergo a screening process to determine eligibility of study entry.
      Peripheral blood, tissue sample and imaging examinations of eligible patients will be
      collected for further analysis. Data collected will be used to develop a multi-omics lung
      cancer diagnosis model.
    
  